News Spyre deprioritises arthritis drug after Phase 2 results Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.
News Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.
News Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.
News Expanded US Imaavy approval first ever for wAIHA The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).
News Final judgement favours TwinStrand in Guardant patent case Court issues final judgement in favour of TwinStrand and the University of Washington in their patent infringement suit against Guardant Health.
News Trodelvy gets EU nod for first-line triple-neg breast cancer A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.